{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:32:55Z","timestamp":1777649575547,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Singapore Ministry of Health\u2019s National Medical Research Council , Open Fund \u2013 Young Individual Research Grant","award":["OF-YIRG, MOH-001248"],"award-info":[{"award-number":["OF-YIRG, MOH-001248"]}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["Singapore Translational Research (STaR) Investigator Award (NMRC\/STaR\/0030\/2018)"],"award-info":[{"award-number":["Singapore Translational Research (STaR) Investigator Award (NMRC\/STaR\/0030\/2018)"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["Clinician Scientist-Individual Research Grants (CS-IRG) (MOH-001091, CIRG23jul-0006)"],"award-info":[{"award-number":["Clinician Scientist-Individual Research Grants (CS-IRG) (MOH-001091, CIRG23jul-0006)"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019579","name":"SingHealth","doi-asserted-by":"publisher","award":["Singhealth-Duke-NUS AM Position grant"],"award-info":[{"award-number":["Singhealth-Duke-NUS AM Position grant"]}],"id":[{"id":"10.13039\/100019579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The field of regenerative medicine for Parkinson\u2019s disease (PD) has reached a pivotal moment. After decades of preclinical research, recent first-in-human clinical trials demonstrated that cell replacement therapy using stem cell-derived dopaminergic neurons is not only feasible and safe but also shows promising signs of efficacy. Here we analyze three landmark 2025 studies, including the phase I\/II trial of allogeneic induced pluripotent stem cell-derived dopaminergic progenitors, that mark a significant leap forward for PD therapy. We discuss principles underpinning the therapy, the historical context of fetal tissue transplants, findings from recent trials, and critical challenges. The convergence of robust cell manufacturing, precise stereotactic surgery, and advanced neuroimaging provides compelling evidence that stem cell-based therapies are potentially a viable treatment paradigm for PD.<\/jats:p>","DOI":"10.1186\/s40035-026-00556-2","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:45:22Z","timestamp":1777445122000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A new dawn for Parkinson\u2019s disease: commentary on the emergence of stem cell-based therapies"],"prefix":"10.1186","volume":"15","author":[{"given":"Rosalie","family":"Elvira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wai Hon","family":"Chooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eng King","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi Dong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"556_CR1","unstructured":"Zahoor I SA, Haq E. Pharmacological treatment of Parkinson\u2019s disease. In: Parkinson\u2019s disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane (AU): Codon Publications; 2018. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK536726\/"},{"issue":"6","key":"556_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1177\/1756285609339382","volume":"2","author":"SJ Groiss","year":"2009","unstructured":"Groiss SJ, Wojtecki L, S\u00fcdmeyer M, Schnitzler A. Review: deep brain stimulation in Parkinson\u2019s disease. Ther Adv Neurol Disord. 2009;2(6):379\u201391.","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"556_CR3","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1602\/neurorx.1.4.382","volume":"1","author":"O Lindvall","year":"2004","unstructured":"Lindvall O, Bj\u00f6rklund A. Cell therapy in Parkinson\u2019s disease. NeuroRx. 2004;1(4):382\u201393.","journal-title":"NeuroRx"},{"issue":"5","key":"556_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/35072572","volume":"2","author":"SB Dunnett","year":"2001","unstructured":"Dunnett SB, Bj\u00f6rklund A, Lindvall O. Cell therapy in Parkinson\u2019s disease\u2013stop or go? Nat Rev Neurosci. 2001;2(5):365\u20139.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"556_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.stem.2010.07.003","volume":"7","author":"RA Barker","year":"2010","unstructured":"Barker RA, Kuan W-L. Graft-induced dyskinesias in Parkinson\u2019s disease: What is it all about? Cell Stem Cell. 2010;7(2):148\u20139.","journal-title":"Cell Stem Cell"},{"issue":"4","key":"556_CR6","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/s44319-024-00099-5","volume":"25","author":"T Sawai","year":"2024","unstructured":"Sawai T, Kataoka M. The ethical and legal challenges of human foetal brain tissue-derived organoids. EMBO Rep. 2024;25(4):1700\u20133.","journal-title":"EMBO Rep"},{"issue":"8064","key":"556_CR7","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41586-025-08700-0","volume":"641","author":"N Sawamoto","year":"2025","unstructured":"Sawamoto N, Doi D, Nakanishi E, Sawamura M, Kikuchi T, Yamakado H, et al. Phase I\/II trial of iPS-cell-derived dopaminergic cells for Parkinson\u2019s disease. Nature. 2025;641(8064):971\u20137.","journal-title":"Nature"},{"issue":"8064","key":"556_CR8","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41586-025-08845-y","volume":"641","author":"V Tabar","year":"2025","unstructured":"Tabar V, Sarva H, Lozano AM, Fasano A, Kalia SK, Yu KKH, et al. Phase I trial of hES cell-derived dopaminergic neurons for Parkinson\u2019s disease. Nature. 2025;641(8064):978\u201383.","journal-title":"Nature"},{"issue":"25","key":"556_CR9","doi-asserted-by":"publisher","first-page":"7036","DOI":"10.1016\/j.cell.2025.09.010","volume":"188","author":"JW Chang","year":"2025","unstructured":"Chang JW, Na HK, Chang KW, Park CW, Kim D-H, Park S, et al. Phase 1\/2a clinical trial of hESC-derived dopamine progenitors in Parkinson\u2019s disease. Cell. 2025;188(25):7036-48.e11.","journal-title":"Cell"},{"issue":"12","key":"556_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2025-107597","volume":"15","author":"G Paul","year":"2025","unstructured":"Paul G, Bjartmarz H, Bj\u00f6rklund A, Cutting E, Evans A, Harry B, et al. STEM-PD trial protocol: a multi-centre, single-arm, first-in-human, dose-escalation trial, investigating the safety and tolerability of intraputamenal transplantation of human embryonic stem cell-derived dopaminergic cells for Parkinson\u2019s disease. BMJ Open. 2025;15(12):e107597.","journal-title":"BMJ Open"},{"key":"556_CR11","first-page":"265","volume-title":"Progress in brain research","author":"P Brundin","year":"2010","unstructured":"Brundin P, Barker RA, Parmar M. Neural grafting in Parkinson\u2019s disease: problems and possibilities. In: Bj\u00f6rklund A, Cenci MA, editors. Progress in brain research, vol. 184. London: Elsevier; 2010. p. 265\u201394."},{"key":"556_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41587-025-02567-2","volume":"44","author":"RA Barker","year":"2025","unstructured":"Barker RA, Lao-Kaim NP, Guzman NV, Athauda D, Bjartmarz H, Bj\u00f6rklund A, et al. The TransEuro open-label trial of human fetal ventral mesencephalic transplantation in patients with moderate Parkinson\u2019s disease. Nat Biotechnol. 2025;44:70\u20138.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"556_CR13","volume":"2015","author":"E Tronci","year":"2015","unstructured":"Tronci E, Fidalgo C, Carta M. Foetal cell transplantation for Parkinson\u2019s disease: focus on graft-induced dyskinesia. Parkinsons Dis. 2015;2015(1):563820.","journal-title":"Parkinsons Dis"},{"issue":"7378","key":"556_CR14","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature10648","volume":"480","author":"S Kriks","year":"2011","unstructured":"Kriks S, Shim J-W, Piao J, Ganat YM, Wakeman DR, Xie Z, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson\u2019s disease. Nature. 2011;480(7378):547\u201351.","journal-title":"Nature"},{"issue":"9","key":"556_CR15","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1038\/nprot.2017.078","volume":"12","author":"S Nolbrant","year":"2017","unstructured":"Nolbrant S, Heuer A, Parmar M, Kirkeby A. Generation of high-purity human ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation. Nat Protoc. 2017;12(9):1962\u201379.","journal-title":"Nat Protoc"},{"issue":"2","key":"556_CR16","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/brain\/awp328","volume":"133","author":"S Grealish","year":"2010","unstructured":"Grealish S, J\u00f6nsson ME, Li M, Kirik D, Bj\u00f6rklund A, Thompson LH. The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson\u2019s disease. Brain. 2010;133(2):482\u201395.","journal-title":"Brain"},{"issue":"11","key":"556_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.mocell.2025.100284","volume":"48","author":"L Puspita","year":"2025","unstructured":"Puspita L, Deline M, Shim J-w. Dual SMAD inhibition as a versatile platform in human pluripotent stem cell\u2013based regenerative medicine and disease modeling. Mol Cells. 2025;48(11):100284.","journal-title":"Mol Cells"},{"issue":"11","key":"556_CR18","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1038\/s41380-022-01628-1","volume":"27","author":"H Li","year":"2022","unstructured":"Li H, Jiang H, Li H, Li L, Yan Z, Feng J. Generation of human A9 dopaminergic pacemakers from induced pluripotent stem cells. Mol Psychiatry. 2022;27(11):4407\u201318.","journal-title":"Mol Psychiatry"},{"issue":"6","key":"556_CR19","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3171\/2024.4.JNS24367","volume":"141","author":"ME Emborg","year":"2024","unstructured":"Emborg ME, Mancinelli A, Colwell JC, Zinnen AD, Pape B, Brunner K, et al. Preclinical evaluation of transaxial intraputaminal trajectory for enhanced distribution of grafted cells in Parkinson\u2019s disease. J Neurosurg. 2024;141(6):1554\u201366.","journal-title":"J Neurosurg"},{"issue":"5","key":"556_CR20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.4252\/wjsc.v6.i5.651","volume":"6","author":"M Otsu","year":"2014","unstructured":"Otsu M, Nakayama T, Inoue N. Pluripotent stem cell-derived neural stem cells: from basic research to applications. World J Stem Cells. 2014;6(5):651\u20137.","journal-title":"World J Stem Cells"},{"issue":"1","key":"556_CR21","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1186\/s12967-023-04484-x","volume":"21","author":"F Wang","year":"2023","unstructured":"Wang F, Sun Z, Peng D, Gianchandani S, Le W, Boltze J, et al. Cell-therapy for Parkinson\u2019s disease: a systematic review and meta-analysis. J Transl Med. 2023;21(1):601.","journal-title":"J Transl Med"},{"issue":"16","key":"556_CR22","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.3390\/s24165238","volume":"24","author":"R Monfaredi","year":"2024","unstructured":"Monfaredi R, Concepcion-Gonzalez A, Acosta Julbe J, Fischer E, Hernandez-Herrera G, Cleary K, et al. Automatic path-planning techniques for minimally invasive stereotactic neurosurgical procedures\u2014a systematic review. Sensors. 2024;24(16):5238.","journal-title":"Sensors"},{"issue":"7","key":"556_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41422-024-00971-y","volume":"34","author":"T-Y Park","year":"2024","unstructured":"Park T-Y, Jeon J, Cha Y, Kim K-S. Past, present, and future of cell replacement therapy for Parkinson\u2019s disease: a novel emphasis on host immune responses. Cell Res. 2024;34(7):479\u201392.","journal-title":"Cell Res"},{"issue":"16","key":"556_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cells14161248","volume":"14","author":"H Zhang","year":"2025","unstructured":"Zhang H, Zhou H, Xia X, Cao Q, Liu Y. Hypoimmunogenic human iPSCs for repair and regeneration in the CNS. Cells. 2025;14(16):1248.","journal-title":"Cells"},{"issue":"1","key":"556_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02237-4","volume":"4","author":"S Petrus-Reurer","year":"2021","unstructured":"Petrus-Reurer S, Romano M, Howlett S, Jones JL, Lombardi G, Saeb-Parsy K. Immunological considerations and challenges for regenerative cellular therapies. Commun Biol. 2021;4(1):798.","journal-title":"Commun Biol"},{"issue":"1","key":"556_CR26","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s13287-022-03129-y","volume":"13","author":"M Norte-Mu\u00f1oz","year":"2022","unstructured":"Norte-Mu\u00f1oz M, Gallego-Ortega A, Lucas-Ruiz F, Gonz\u00e1lez-Riquelme MJ, Changa-Espinoza YI, Galindo-Romero C, et al. Immune recognition of syngeneic, allogeneic and xenogeneic stromal cell transplants in healthy retinas. Stem Cell Res Ther. 2022;13(1):430.","journal-title":"Stem Cell Res Ther"},{"key":"556_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.biomaterials.2015.09.039","volume":"74","author":"T-Y Wang","year":"2016","unstructured":"Wang T-Y, Bruggeman KF, Kauhausen JA, Rodriguez AL, Nisbet DR, Parish CL. Functionalized composite scaffolds improve the engraftment of transplanted dopaminergic progenitors in a mouse model of Parkinson\u2019s disease. Biomaterials. 2016;74:89\u201398.","journal-title":"Biomaterials"},{"issue":"9","key":"556_CR28","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.stem.2025.07.012","volume":"32","author":"A Morizane","year":"2025","unstructured":"Morizane A, Yamasaki E, Shindo T, Anazawa T, Sawamoto N, Shima A, et al. Control of immune response in an iPSC-based allogeneic cell therapy clinical trial for Parkinson\u2019s disease. Cell Stem Cell. 2025;32(9):1346-55.e3.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"556_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-021-00190-7","volume":"42","author":"T Kamatani","year":"2022","unstructured":"Kamatani T, Otsuka R, Murata T, Wada H, Takahashi T, Mori A, et al. Evaluation of immunosuppression protocols for MHC-matched allogeneic iPS cell-based transplantation using a mouse skin transplantation model. Inflamm Regen. 2022;42(1):4.","journal-title":"Inflamm Regen"},{"issue":"3","key":"556_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/lifemedi\/lnaf016","volume":"4","author":"Z Hong","year":"2025","unstructured":"Hong Z, Zhao Y, Pahlavan S, Wang X, Han S, Wang X, et al. iPSC modification strategies to induce immune tolerance. Life Med. 2025;4(3):lnaf016.","journal-title":"Life Med"},{"issue":"1","key":"556_CR31","doi-asserted-by":"publisher","first-page":"7871","DOI":"10.1038\/s41467-023-43471-0","volume":"14","author":"M Maimaitili","year":"2023","unstructured":"Maimaitili M, Chen M, Febbraro F, Ucuncu E, Kelly R, Niclis JC, et al. Enhanced production of mesencephalic dopaminergic neurons from lineage-restricted human undifferentiated stem cells. Nat Commun. 2023;14(1):7871.","journal-title":"Nat Commun"},{"key":"556_CR32","doi-asserted-by":"publisher","DOI":"10.1101\/2025.01.06.631400","author":"TW Kim","year":"2025","unstructured":"Kim TW, Piao J, Bocchi VD, Koo SY, Choi SJ, Chaudhry F, et al. Enhanced yield and subtype identity of hPSC-derived midbrain dopamine neuron by modulation of WNT and FGF18 signaling. bioRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.01.06.631400.","journal-title":"bioRxiv"},{"issue":"1","key":"556_CR33","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1038\/s41467-022-30777-8","volume":"13","author":"Z Alekseenko","year":"2022","unstructured":"Alekseenko Z, Dias JM, Adler AF, Kozhevnikova M, van Lunteren JA, Nolbrant S, et al. Robust derivation of transplantable dopamine neurons from human pluripotent stem cells by timed retinoic acid delivery. Nat Commun. 2022;13(1):3046.","journal-title":"Nat Commun"},{"issue":"11","key":"556_CR34","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/j.stem.2025.10.001","volume":"32","author":"X Zhang","year":"2025","unstructured":"Zhang X, Wu Z, He H, Guan Q, Ouyang Q, Wang R, et al. 3D-generation of high-purity midbrain dopaminergic progenitors and lineage-guided refinement of grafts supports Parkinson\u2019s disease cell therapy. Cell Stem Cell. 2025;32(11):1758-72.e8.","journal-title":"Cell Stem Cell"},{"issue":"8","key":"556_CR35","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/jnr.24668","volume":"98","author":"Y Miyawaki","year":"2020","unstructured":"Miyawaki Y, Samata B, Kikuchi T, Nishimura K, Takahashi J. Zonisamide promotes survival of human-induced pluripotent stem cell-derived dopaminergic neurons in the striatum of female rats. J Neurosci Res. 2020;98(8):1575\u201387.","journal-title":"J Neurosci Res"},{"issue":"4","key":"556_CR36","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s13311-020-00924-4","volume":"17","author":"MAC Sy","year":"2020","unstructured":"Sy MAC, Fernandez HH. Pharmacological treatment of early motor manifestations of Parkinson disease (PD). Neurotherapeutics. 2020;17(4):1331\u20138.","journal-title":"Neurotherapeutics"},{"key":"556_CR37","unstructured":"Aspen-Neuroscience. Phase 1\/2a dose escalation study of ANPD001 in sporadic Parkinson disease. 2025. [cited Aspen-Neuroscience Enrolling by invitation]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06344026."}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-026-00556-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-026-00556-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-026-00556-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:45:26Z","timestamp":1777445126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40035-026-00556-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["556"],"URL":"https:\/\/doi.org\/10.1186\/s40035-026-00556-2","relation":{},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read the final version of the manuscript and agreed to submit it for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}